Cedric
☆    

Singapore,
2014-04-29 15:50
(4044 d 12:46 ago)

Posting: # 12900
Views: 7,343
 

 LLOQ < 5% Cmax [Bioanalytics]

What is the basis behind the requirement that the LLOQ of the calibration range has to be less than 5% of Cmax? Is the BE result still valid if the LLOQ is > 5% of Cmax?


Edit: Please follow the Forum’s Policy. [Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2014-04-29 16:19
(4044 d 12:16 ago)

@ Cedric
Posting: # 12901
Views: 6,575
 

 Carry-over

Hi Cedric,

❝ What is the basis behind the requirement that the LLOQ of the calibration range has to be less than 5% of Cmax?


The cut-off for excluding subjects (“substantial” carry-over from earlier periods in cross-over studies due to a too short wash-out phase) in many guidelines on BE is 5% of Cmax.

❝ Is the BE result still valid if the LLOQ is > 5% of Cmax?


≤5% of Cmax is the target mentioned in guidelines on bioanalytical method validation. Now the question is: Where to get the value of Cmax from? I would suggest to be conservative (i.e., not work with an average reported in the literature) but take between-subject variability into account. Many GLs on BE require ≥80% of AUC and/or ≥3t½ to be covered by measured data. There is no simple relationship between the suggested LLOQ and these metrics, but should be seen as a reasonably good starting point. Some drugs are metabolized by enzymes showing genetic polymorphism. Even if you have taken that into account (extensive metabolizers result in a high LLOQ/Cmax-ratio) sometimes you face ultra-fast metabolizers… However, in a cross-over study the test/reference-ratio would still be valid.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Cedric
☆    

Singapore,
2014-04-30 16:24
(4043 d 12:12 ago)

@ Helmut
Posting: # 12902
Views: 6,418
 

 Carry-over

❝ The cut-off for excluding subjects (“substantial” carry-over from earlier periods in cross-over studies due to a too short wash-out phase) in many guidelines on BE is 5% of Cmax.


Thanks for the clear explanation. A quick clarification.. the rules for excluding subjects with substantial carry-over should be the pre-dose level is greater than 5 % Cmax. what is the relationship between the predose < 5 % Cmax and LLOQ < 5 % Cmax.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]
Shuanghe
★★  

Spain,
2014-04-30 17:35
(4043 d 11:01 ago)

@ Cedric
Posting: # 12903
Views: 6,373
 

 Carry-over

Hi Cedric,

❝ ... A quick clarification.. the rules for excluding subjects with substantial carry-over should be the pre-dose level is greater than 5 % Cmax. what is the relationship between the predose < 5 % Cmax and LLOQ < 5 % Cmax.


In order to be able to exclude those subject who has predose > 5% Cmax firstly you need to have method to detect that concentration (hence the LLOQ of 5% of Cmax). To give an example, if the LLOQ of your method is 10% of the Cmax, what if a subject with predose of 8% of the Cmax? He/she should be excluded but you are unable to detect such subject because the predose concentration is below your LLOQ.

All the best,
Shuanghe
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
31 visitors (0 registered, 31 guests [including 8 identified bots]).
Forum time: 04:36 CEST (Europe/Vienna)

Far better an approximate answer to the right question,
which is often vague, than an exact answer to the wrong question,
which can always be made precise.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5